Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications by Wenya Linda Bi et al.
July 2016 | Volume 3 | Article 401
Mini Review
published: 06 July 2016
doi: 10.3389/fsurg.2016.00040
Frontiers in Surgery | www.frontiersin.org
Edited by: 
Nicholas Theodore, 
Barrow Neurological Institute, USA
Reviewed by: 
Amgad Hanna, 
University of Wisconsin, USA  
Leonardo Welling, 
State University of Ponta Grossa, 
Brazil
*Correspondence:
Ian F. Dunn 
idunn@partners.org
Specialty section: 
This article was submitted 
to Neurosurgery, 
a section of the journal 
Frontiers in Surgery
Received: 16 February 2016
Accepted: 27 June 2016
Published: 06 July 2016
Citation: 
Bi WL, Zhang M, Wu WW, Mei Y and 
Dunn IF (2016) Meningioma 
Genomics: Diagnostic, Prognostic, 
and Therapeutic Applications. 
Front. Surg. 3:40. 
doi: 10.3389/fsurg.2016.00040
Meningioma Genomics: Diagnostic,
Prognostic, and Therapeutic 
Applications
 
Wenya Linda Bi, Michael Zhang, Winona W. Wu, Yu Mei and Ian F. Dunn*
Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
There has been a recent revolution in our understanding of the genetic factors that 
drive meningioma, punctuating an equilibrium that has existed since Cushing’s germinal 
studies nearly a century ago. A growing appreciation that meningiomas share similar 
biologic features with other malignancies has allowed extrapolation of management 
strategies and lessons from intra-axial central nervous system neoplasms and systemic 
cancers to meningiomas. These features include a natural proclivity for invasion, fre-
quent intratumoral heterogeneity, and correlation between biologic profile and clinical 
behavior. Next-generation sequencing has characterized recurrent somatic mutations in 
NF2, TRAF7, KLF4, AKT1, SMO, and PIK3CA, which are collectively present in ~80% of 
sporadic meningiomas. Genomic features of meningioma further associate with tumor 
location, histologic subtype, and possibly clinical behavior. Such genomic decryption, 
along with advances in targeted pharmacotherapy, provides a maturing integrated view 
of meningiomas. We review recent advances in meningioma genomics and probe their 
potential applications in diagnostic, therapeutic, and prognostic frontiers.
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Meningioma genetics are undergoing a revolution in taxonomy and molecular stratification, punc-
tuating an equilibrium that has existed since Cushing’s germinal studies nearly a century ago (1). 
The understanding of meningiomas rests on a growing appreciation that these tumors share similar 
features with other intra-axial central nervous system (CNS) neoplasms as well as systemic cancers. 
Moreover, maturing technologies in genomics and immunotherapy are increasingly intersecting 
to provide an integrated view on meningioma biology. We review recent advances in meningioma 
genomics and probe their potential applications in diagnostic, therapeutic, and prognostic frontiers.
MeninGiOMA HiSTOPATHOLOGiC CLASSiFiCATiOn
Meningiomas account for over a third of all primary CNS tumors diagnosed in the United States, 
with ~18,000 new cases diagnosed annually and a prevalence of 97.5/100,000 individuals, making 
them the most common primary intracranial neoplasms in adults (2, 3). Most meningiomas are 
considered benign. A small, but growing, proportion display aggressive behavior characterized by 
invasive growth patterns and higher rates of recurrence (4).
Meningiomas are classified by the World Health Organization (WHO) system as grades I, II, and 
III, with higher grades associated with greater rates of morbidity and mortality (Figure 1) (5). Grade 
I meningiomas display a broad range of morphologic features and are considered histologically 
benign, with fewer than 4 mitoses/10 microscopic high-power fields (HPF). Nine subtypes of benign 
meningiomas are recognized by the WHO: meningothelial, fibroblastic, transitional (containing both 
FiGURe 1 | Demographics, wHO diagnostic criteria, histologic subtypes, and clinical outcomes at 10 years follow-up for meningioma, as stratified 
by grade.  §Clinical outcomes are influenced by age, comorbidities, extent of resection, adjuvant therapy, and tumor location.
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meningothelial and fibroblastic components), psammomatous, 
angiomatous, microcystic, secretory, lymphoplasmacyte-rich, 
and metaplastic.
Grade II, also known as atypical, meningiomas are defined by 
the presence of 4–19 mitoses/10 HPF or 3 of 5 criteria: sheet-like 
growth, spontaneous necrosis, high nuclear to cytoplasmic ratio, 
prominent nucleoli, and increased cellularity. Meningiomas with 
two or less of the five atypical features are classified as grade I 
meningiomas with atypical features, and incur a higher risk of 
recurrence than benign meningiomas without atypical features 
(6). Two distinct histologic variants, clear cell and chordoid, are 
considered grade II meningiomas as well. In addition, the pres-
ence of brain invasion implies a similar recurrence rate and risk 
of mortality as atypical meningiomas (7).
Grade III meningioma is synonymous with anaplastic or 
malignant meningioma. Morphologically, they can resemble 
sarcoma or carcinoma, challenging pathologic diagnosis, and also 
include the papillary and rhabdoid histologic variants. Grade III 
meningiomas harbor a mitotic index of 20 or greater per 10 HPF, 
and classically lose markers of differentiation, such as epithelial 
membrane antigen. Patients with anaplastic meningiomas 
observe an aggressive clinical course of tumor recurrence and 
premature mortality.
CHALLenGeS in MeninGiOMA 
MAnAGeMenT
The histopathologic classification of meningioma provides a 
powerful harbinger for its natural history. However, clinical 
outcome in a subset of patients belies the designated pathologic 
grade for the tumor. Improved understanding of the genomic 
underpinnings of meningioma offers new strategies for molecular 
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stratification and rationally guided therapies. We first highlight 
some of the challenges facing meningioma management, then 
review recent advances in meningioma genomics, and draw upon 
lessons learned from other cancers.
Limitations of Diagnostic Criteria
On initial detection of an extra-axial mass lesion consistent 
with meningioma on imaging, no reliable parameters exist 
to date for predicting tumor grade, and ultimately, biologic 
course. A number of radiographic metrics are under investiga-
tion, including nature of the tumor–brain interface, intratumor 
heterogeneity, lesion irregularity, intrinsic tumor diffusion 
and perfusion characteristics, and peritumoral edema, but all 
merit further validation. Furthermore, tumor location, such as 
parasagittal and falcine, may portend a more aggressive nature 
to the meningioma. Ultimately, mass effect leading to existing 
or impending symptoms, steadfast radiographic growth over a 
period of observation, and patient preference dictate the decision 
to intervene on a suspected meningioma.
Variations in operative philosophy, operative technique, 
and choice and timing of radiation permeate clinical practice. 
In general, maximal surgical resection without compromise of 
neurologic function imparts the most optimal prognosis for the 
patient. Standard of care typically invokes adjuvant radiation 
therapy for malignant meningiomas, with greater variability in 
the administration and timing of radiation for atypical meningi-
omas. This variability in management strategy for intermediate 
grade meningiomas is further complicated by shifts in diagnostic 
criteria over time (5, 8–10).
For example, application of the 2000 instead of the 1993 WHO 
guidelines results in a change in classification in up to 30% of 
high-grade meningiomas, often from a higher grade to lower 
grade (11). The 2007 WHO guidelines introduced less of a para-
digm shift, but brain invasion remained ambiguous as a marker 
for atypical meningioma (12). The evolution of WHO grading 
scales associates with an improved correlation between grade and 
survival (13). However, inter-observer differences and representa-
tive sampling of select sections from large tumors may bias the 
final grading and, therefore, prediction of natural history. As with 
other CNS tumors, unbiased criteria for diagnostic arbitration, 
such as molecular signatures, can abet definitive stratification of 
tumor class. Furthermore, an association between such molecular 
signatures, tumor phenotype, and, ultimately, prognosis would 
improve initial planning for treatment interventions.
Meningioma as an invasive Tumor
Independent of tumor classification, the clinical course of 
meningiomas following surgical resection highlights its biologic 
proclivity for invasiveness. In Simpson’s classic analysis of symp-
tomatic recurrence following resection of meningiomas, residual 
dural attachment and juxtaposition to venous sinuses  –  which 
serve as a potential haven for neoplastic cells in the absence of 
bulk tumor – were associated with significantly higher rates of 
recurrence (14). Furthermore, meningiomas with benign histo-
pathologic features that invade the brain exhibit a similar likeli-
hood of recurrence as higher grade, atypical, meningiomas. Thus, 
despite being the quintessential icon of CNS extra-axial tumors, 
the invasive potential of meningioma cells highlights an inherent 
limitation to debulking strategies and should be accounted for in 
therapeutic strategies.
intratumoral Heterogeneity
Surgical resection aside, radiation serves as a common adjuvant 
treatment for meningioma, especially in high-grade and recur-
rent tumors. A few biological agents, such as hydroxyurea and 
somatostatin inhibitors, have been trialed with limited success 
in meningiomas refractory to standard treatment modalities 
(15). These treatments rely upon the biologic response of non-
senescent tumor cells. Additionally, the development of targeted 
pharmacologic inhibitors, as widely studied for systemic cancers 
and discussed below for meningioma, presumes a global distribu-
tion of the oncogenic driver or modulator target. The presence of 
intratumoral heterogeneity poses a fundamental impediment to 
the efficacy of these therapeutic strategies.
The observation of meningioma heterogeneity stems from a 
number of potential etiologies, including intratumoral necrosis, 
cystic degeneration, heterogeneous tumor cell expansion, imbal-
ances in cell density, and hemorrhage. In particular, subclonal 
expansion within an admixture of functionally distinct cancer 
cells has been posited to account for incomplete treatment 
response, acquired and innate treatment resistance, and disease 
relapse for malignancies, such as glioblastoma and systemic can-
cers. Similarly, molecular and cellular heterogeneity is increas-
ingly appreciated in meningioma (16), and may present a similar 
challenge to the development of therapeutic strategies.
These characteristics of meningiomas echo challenges posed 
by other tumors, some of which serve as exemplars in decrypting 
the molecular code toward a more unified front in diagnosis and 
treatment, as discussed below.
GenOMiCS OF MeninGiOMA
Meningioma represents one of the first tumors associated with 
a genomic driver, with the initial identification of neurofibromin 
(NF2), the causative gene for neurofibromatosis 2 (NF2), in which 
50–75% of patients develop one or more meningiomas. Sporadic 
low- and high-grade meningiomas are also observed to harbor 
mutations, allelic inactivation, and loss of the NF2 in ~40–60% 
of tumors, resulting in alteration of its protein derivative, Merlin 
(17–20). The development of meningiomas in NF2-knockout 
mice corroborates its role as an early oncogenic driver in menin-
gioma tumorigenesis (21, 22).
More recently, several additional recurrent somatic muta-
tions have been identified through next-generation sequencing 
approaches, which are collectively present in ~40% of sporadic 
meningiomas (Figure  2A) (19, 20, 23). These genes are the 
pro-apoptotic E3 ubiquitin ligase TNF receptor-associated factor 
7 (TRAF7), the pluripotency transcription factor Kruppel-like 
factor 4 (KLF4), the proto-oncogene v-Akt murine thymoma viral 
oncogene homolog 1 (AKT1), the Hedgehog pathway signaling 
member smoothened (SMO), and the oncogene PIK3CA. Notably, 
mutations of these genes in meningiomas occur to large degree 
without concurrent alteration of NF2 or loss of chromosome 22.
FiGURe 2 | (A) Recurrent NF2, AKT1, SMO, TRAF7, KLF4, and PIK3CA mutations are collectively present in over 80% of grade I meningiomas. Mutations in AKT1, 
KLF4, and PIK3CA overlap with TRAF7, but not with each other, and largely occur in a mutually exclusive pattern with NF2 and SMO. Oncogenic driver mutations 
remain unclear for ~20% of meningiomas [Data aggregated from Ref. (19, 20, 23, 41)]. (B) Recurrent chromosomal copy number alterations in meningioma. 
Chromosomal arm-level gains (red) and losses (blue) are observed with increasing frequency in higher-grade meningiomas, compared to grade I meningiomas. 
§Polysomy 5 is observed in angiomatous subtype of grade I meningiomas [Data adapted from Ref. (5, 32)].
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The most common of these is TRAF7, located on chromosome 
16p13, which harbors a mutation in 12–25% of meningiomas 
(20). TRAF7 mutations frequently co-occur with mutations 
in KLF4, AKT1, or PIK3CA, and are mutually exclusive with 
SMO and NF2 mutations (20, 23, 24). A recurrent mutation in 
KLF4K409Q, located on chromosome 9q31 and resulting in a lysine 
to glutamine substitution at codon 409 (K409Q), represents the 
next most frequent somatic alteration observed to date – affecting 
~15% of benign meningiomas. This may recapitulate embryologic 
mechanisms to spur tumor formation, given the role of KLF4 as a 
transcription factor that promotes reprograming of differentiated 
somatic cells back to a pluripotent state in normal development 
(25). Another recurrent mutation in AKT1, located on chromo-
some 14q32, is observed in 6.8% of meningiomas and produces 
a glutamic acid to lysine substitution at codon 17 (E17K) (20, 
26). AKT1E17K mutation results in downstream activation of the 
PI3K/AKT/mTOR oncogenic pathway, rendering it targetable by 
selective AKT inhibitors, several of which are currently under 
investigation for the treatment of cancers of the breast, lung, and 
colon, among others (27). Oncogenic mutations in PIK3CA are 
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observed in ~7% of non-NF2-mutant meningiomas, and occur 
mutually exclusive of AKT1 and SMO mutations, although they 
frequently co-occur with TRAF7 mutations (23). Lastly, ~5.5% of 
benign meningiomas, or more than 10% of meningiomas without 
NF2 alteration, express mutations in SMO (19, 20). These SMO 
alterations result in activation of Hedgehog signaling, another 
well-characterized pathway in cancer that is notably dysregu-
lated in basal-cell carcinoma and medulloblastoma (28, 29). In 
basal-cell carcinoma, where over 90% of tumors have mutations 
in either SMO or PTCH, SMO inhibition has been particularly 
effective in the setting of locally advanced and metastatic disease 
(30). Inhibitors of SMO, AKT1, and PIK3CA hold promise as 
molecularly targeted pharmacotherapy in meningioma.
Collectively, these somatic mutations hold significant promise 
for advancing the molecular taxonomy of meningioma. However, 
~20% of meningiomas remain without an identifiable oncogenic 
driver mutation to date (31). Beyond mutations, insertions, and 
deletions at the single nucleotide level, meningiomas harbor a 
classic constellation of chromosomal copy number alterations 
(Figure 2B). Monosomy 22 is the most common chromosomal 
change, observed in 40–70% of meningiomas, across all grades 
(7). Aside from loss of chromosome 22, the copy number land-
scape of benign meningiomas is typically neutral. One exception 
is the angiomatous subtype of grade I meningiomas, which 
notably express multiple polysomies across the genome, most 
commonly of chromosome 5 (32). In comparison, higher-grade 
meningiomas express a markedly higher burden of chromosomal 
losses and gain. These include frequent loss of chromosomes 1p, 
6q, 10, 14q, and 18q, as well as gain of chromosomes 1q, 9q, 12q, 
15q, 17q, and 20q (7, 33, 34). Among these, loss of chromosomes 
1p and 14q is the most frequent cytogenetic abnormality observed 
in meningiomas after chromosome 22, affecting half of grade II 
and nearly all grade III meningiomas (33). Investigations into 
candidate oncogenes on these chromosomal arms have yet to 
elucidate clear drivers for meningioma tumorigenesis.
In addition to mutations and copy number alterations, epi-
genomic changes may provide another complementary biologic 
mechanism in meningioma development and progression (35). 
Overall, all existing evidence suggests a progression in genomic 
complexity in high-grade meningiomas.
APPLiCATiOnS OF MOLeCULAR 
TAXOnOMY in MeninGiOMA
These significant advances in our understanding of meningi-
omas provide an expanding toolbox to formulate a molecular 
taxonomy and explore novel therapeutic options for this surpris-
ingly diverse tumor entity. This paradigm shift toward molecular 
taxonomy is inspired by examples from several tumor types, 
including glioblastoma, medulloblastoma, and ependymoma, 
where molecular stratification has transformed their diagnosis 
and management (36–38). Similarly, associations between 
molecular signatures with characteristic phenotypes, intracranial 
locations, tumor subclass, and clinical prognosis have begun to 
emerge as an increasing number of meningiomas are systemati-
cally characterized.
Genetic Hallmarks of  
Meningioma Subtypes
The histologic subtype and location of meningioma associates 
with its molecular profile (Table S1 in Supplementary Material). 
Grade II and III meningiomas harbor an incremental comple-
ment of chromosomal alterations, as discussed above. Copy 
number gains, especially polysomy 5, are also characteristic of 
angiomatous meningiomas, a grade I subtype (32).
Focally, inactivation of NF2, through copy loss or mutation, 
occurs in 70–80% of fibroblastic and transitional meningiomas. 
By contrast, secretory meningiomas almost uniformly harbor 
mutations in both TRAF7 and KLF4K409Q but not NF2 (24), while 
meningothelial meningiomas are associated with AKT1 muta-
tions (26). Additionally, clear cell meningiomas are associated 
with loss-of-function mutations of SMARCE1 in the hereditary 
multiple spinal meningioma syndrome and some cranial loca-
tions (39, 40).
Interestingly, genetic alterations also correlate with anatomic 
location in some meningiomas. Mutations in SMO or AKT1/
TRAF7 are most frequently observed in meningiomas of the ante-
rior cranial base (19, 20). In comparison, convexity meningiomas 
are more likely to express NF2 mutations and loss of heterozygo-
sity of chromosome 22. The association between tumor location 
and genotype may aid candidate selection in future clinical trials 
that target specific oncogenic mutations.
Predicting Clinical Outcome
Aside from the role of molecular biomarkers in abetting the 
diagnosis of meningioma, one fundamental question in the clini-
cal management of meningioma patients is the risk of recurrence 
following surgical resection. There is particular ambiguity among 
grade II meningiomas, for which no consensus exists regards 
appropriate adjuvant treatment modality and timing. Recently, 
analysis of a cohort of atypical meningiomas following gross 
total resection revealed an association between increased chro-
mosomal copy number alterations and risk of recurrence (41). By 
summing the incidence of broad copy number events across an 
aggregate pool of common chromosomal aberrations in menin-
giomas, this strategy bypasses the limitations of assessing isolated 
molecular candidates in meningioma oncogenesis and offers a 
rapid molecular appraisal of potential outcome through routine 
clinical cytogenetic testing. In other words, patients harboring 
grade II meningiomas with high chromosomal disruption, which 
may have a higher risk of recurrence, may benefit from closer 
surveillance or adjuvant therapies.
The validity of such molecular prognostication strategies 
remains to be proven in future studies. If corroborated, they may 
serve a powerful tool in counseling patients, guiding manage-
ment decisions, and stratifying clinical trials.
Designing Rational Strategies in 
Meningioma Treatment
Elucidation of critical oncogenic drivers in a number of cancers 
(e.g., BRAF in melanoma or KIT in gastrointestinal stromal 
tumors) has enabled targeted therapies in the so-called “mutation-
to-drug” paradigm (42, 43). Such an approach is now feasible in 
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meningioma with the recent identification of AKT1, SMO, and 
PIK3CA mutations, which opens the door for targeted pharma-
cotherapeutics in ~20% of grade I meningiomas. A clinical trial 
targeting AKT1 and SMO is currently underway for progressive 
meningiomas (NCT02523014).
While this genomically stratified trial augurs an exciting 
direction for refractory meningiomas that progress after standard 
therapy, other meningiomas that do not express these mutations, 
including most high-grade tumors, remain devoid of effective 
pharmacologic options. Furthermore, recognition of intratu-
moral cellular and molecular heterogeneity, which may foster 
resistant subclonal growth following targeted therapies, encour-
ages investigation of alternative treatment strategies  –  such as 
immunotherapy (44).
Deployment of the innate and adaptive immune response 
offers an attractive option for genomically complex tumors, where 
presumably a higher neoantigen load is available for immune 
targeting (45, 46). Suppression of inhibitors of T-cell activation, 
known as immune checkpoints, has achieved durable clinical 
responses in several advanced systemic cancers (47). In grade 
II and III meningiomas that progress after surgery and standard 
radiation, a phase 2 clinical trial evaluating checkpoint blockade 
with nivolumab is anticipated to initiate (NCT02648997).
COnCLUSiOn
Contemporary advances in molecular, genomic, epigenetic, 
and immune profiling has ushered a renaissance in the study of 
meningiomas. These systematic approaches suggest a molecular 
taxonomy that promises to influence diagnosis, disease classifica-
tion, and, ultimately, clinical management. Furthermore, appre-
ciation of shared biological characteristics between meningiomas 
and other CNS cancers – including invasiveness and intratumoral 
heterogeneity – may lead to an expansion of the therapeutic arse-
nal in the treatment of this increasingly disparate tumor.
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